ERNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ernexa Therapeutics Inc (ERNA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financials are in a severe decline, there are no positive trading signals, and the technical indicators do not suggest a strong entry point. Additionally, there is no recent news or positive catalysts to support a potential recovery or growth.
The MACD is slightly positive but contracting, RSI is neutral at 32.015, and moving averages are converging, indicating no clear trend. The stock is trading below key support levels, with the current price at 0.2646, below S1 (0.268). Overall, the technical indicators suggest a bearish trend.
NULL. No recent news, positive trading trends, or significant events to drive the stock upward.
The stock price has declined significantly (-8.16% in regular market and -1.96% post-market). Financial performance is extremely poor, with revenue, net income, EPS, and gross margin all showing sharp declines. There are no hedge fund or insider trading trends to suggest confidence in the stock.
In Q3 2025, revenue dropped to 0 (-100% YoY), net income dropped to -$1,240,000 (-95.34% YoY), EPS fell to -0.15 (-99.80% YoY), and gross margin dropped to 0 (-100% YoY). The company is experiencing severe financial deterioration.
No analyst rating or price target changes available.
